BNET Industries
Market Cap:$237.6M
Last Fiscal Year Sales:$28.7M
- Public
- US
Dow Jones Description
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), is a biopharmaceutical company that acquires, develops and commercializes a diversified portfolio of oncology and other drug candidates that meet critical health challenges for which there are few other treatment options. The Company's pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease. Spectrum's passion to identify, develop and deliver better options for people suffering from cancer is behind every action they take. At Spectrum, everyone is committed to excellence and strives to make a difference every day.
Number of Employees 84
Contact Information
157 Technology Dr
Irvine, California 92618-2402
(949) 788-6700
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Spectrum Pharmaceuticals and Handok sign collaboration agreement
-
Drug Maker Spectrum Signs Deal With Japanese Company
-
Spectrum touts increase in Zevalin sales
-
Spectrum Pharmaceuticals, Inc. SPPI JOBS Inks Deal with Korea's Handok Pharmaceuticals for Cancer Drug; Handok...
-
UPDATE 2-Spectrum says CMS OKs reimbursement of its cancer drug
-
Spectrum Pharmaceuticals Secures $50 Million from Institutional Investors
-
Unusual 11 Mid-Day Movers 9/8: OPXA, ITLN, CBY, ORH Higher; OSIR, UBSH, EXXI, SPPI Lower
-
Morgan Joseph Downgrades Spectrum Pharmaceuticals SPPI to Hold
-
PREVIEW-Spectrum's cancer drug expected to cross FDA hurdle
-
Spectrum Pharmaceuticals reports Q2 net loss
-
Spectrum Pharma Provides FDA With Addl. Details For Cancer Drug Zevalin - Update
-
Spectrum Pharmaceuticals, Inc. SPPI Receives $10 Million from Two Institutional Investors at $5.83 Per Share
News & Analysis
Filter by
justin m. hall and spectrum pharmaceuticals inc. - All News and Analysis
Spectrum Pharmaceuticals: Undervalued and (Now) Oversold
Seeking Alpha
- 2009-09-24
ROUND ONE During the last pullback, Spectrum Pharmaceuticals SPPI began to sell-off on June 30 after shares of the company had reached the first new multi-year high since July 2007. On June 30, SPPI topped at $8.15 and closed at $7.65. by Justin M. Hall
Spectrum Pharmaceuticals: Oversold and Undervalued
Seeking Alpha
- 2009-07-14
In Monday trading, Spectrum Pharmaceuticals (Nasdaq: SPPI) closed at $4.98 with a market cap of $193 million. Shares broke through and closed below their 50-day MA, $5.02. This suggests that shares of the drug maker are likely oversold. Data Source: e-Signal. by Justin M. Hall
Spectrum Pharmaceuticals: Temporary Setback
Seeking Alpha
- 2009-07-06
Yesterday, Spectrum Pharmaceuticals (Nasdaq: SPPI) announced receipt of a Complete Response Letter (CRL) for Zevalin from the FDA. SPPI submitted a supplemental Biologics License Application sBLA earlier this year for the use of Zevalin as a first-line consolidation therapy for the treatment of non-Hodgkin’s lymphoma (NHL). Zevalin is currently approved...
17 Reasons Why Bayer Might Acquire Spectrum Pharmaceuticals
Seeking Alpha
- 2009-06-30
Spectrum Pharmaceuticals (Nasdaq: SPPI) has two upcoming dates with regulators in the coming months. July 2: Zevalin October 8: Fusilev Bayer Schering Bayer markets Zevalin in Europe and abroad - all countries ex. US....
Spectrum Pharmaceuticals: Undervalued Growth Company with Strong Late-Stage Pipeline
Seeking Alpha
- 2009-06-19
With two potential approvals coming up in the next 120 days, Spectrum Pharmaceuticals (Nasdaq: SPPI) appears to be a hidden gem. APPLES TO APPLES Investor’s Business Daily bases its rankings on the relationship that one company has with other companies within the same industry. In my June 12 article,...
Two Possible Upcoming Approvals for Spectrum Pharmaceuticals
Seeking Alpha
- 2009-06-12
Small cap drug makers are at a unique time in industry history. Over the next three years, many of big pharma's patents are set to expire. As result, some investors perceive that big pharma's pipeline collectively is drying up. The industry is projected to lose tens of billions in market...
- 1
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
Glass Door
Pharma Industry Companies
| Company | Employer Rating |
| Johnson & Johnson |  |
| Merck | |
| Pfizer | |
| Novartis |  |
| Abbott Labs | |
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
